|Bid||19.39 x 1400|
|Ask||23.30 x 800|
|Day's Range||19.36 - 19.94|
|52 Week Range||16.18 - 25.43|
|Beta (3Y Monthly)||1.09|
|PE Ratio (TTM)||395.51|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.25|
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 8 months is one of those periods, as the Russell 2000 […]
Amphastar Pharmaceuticals, Inc. (AMPH) announced today that Jason Shandell, President, will be presenting at the BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 2:40 p.m. Eastern Time, New York, NY. This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com . Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
Amphastar Pharmaceuticals, Inc., (AMPH) today announced that it has entered into a settlement agreement (the “Settlement Agreement”) with Momenta Pharmaceuticals Inc. and Sandoz Inc., (collectively, “Momenta/Sandoz”).
Low-cost index funds make it easy to achieve average market returns. But if you invest in individual stocks, some are...
Amphastar Pharmaceuticals, Inc. (AMPH) announced today that Bill Peters, CFO, will be presenting at the Raymond James Life Sciences and MedTech Healthcare Conference on Wednesday, June 19, 2019 at 4:10 p.m. Eastern Time, New York, NY. This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com . Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
Amphastar Pharmaceuticals, Inc. (AMPH) announced today that Jason Shandell, President and Bill Peters, CFO, will be presenting at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 8:30 a.m. Eastern Time, New York, NY. This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com . Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
It's not supposed to be a great month for stocks. Over the course of the past 70 years, June has lost ground about as often as it has gained ground, while the average performance for the S&P 500 for the coming month is actually a small loss. And, given the market's May so far, following a red-hot start to the year, it looks like this June could prove particularly problematic.It's not a problem that applies to all tickers, however. There will be exceptions.Some of those exceptions are rooted in new sector rotation, while others are the result of excessive selloffs we've seen take shape in recent weeks. Still, others are stocks that have simply been in unstoppable, steady uptrends that don't appear ready to come to a close anytime soon.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Top Pot Stocks to Buy Whatever the reason, add these seven names to your list of stocks to buy for your best shot at making forward progress in the coming month(s). TerraForm Power (TERP) Click to EnlargeTerraForm Power (NASDAQ:TERP) is a utility-scale renewable energy producer. It owns more than 3,700 megawatts worth of wind and solar energy farms, mostly in the United States.The hype surrounding renewables back in 2013 and 2014 was palpable, giving rise to the company as a publicly traded entity in July 2014, spun-off from troubled (and eventually bankrupt) parent SunEdison.The timing, however, couldn't have been more unfortunate. The buzz, as well as pricing power and its growth rate, peaked in mid-2015. By the end of that year, TERP stock had lost nearly 90% of its value. Most investors mentally wrote it off.Big mistake. Although slow-going and inconsistent, TerraForm Power shares are fighting their way back. While stagnant for the bulk of 2018, the stock appears to be in breakout mode, punching past resistance around $12. There's another ceiling around $14, but with next year's expected revenue growth of 14% also expected to drive per-share earnings from $2.41 to $2.95, moving past that line in the sand could actually prove catalytic. The social and political tides once again favor the idea of renewables. Boston Scientific (BSX) Click to EnlargeBoston Scientific (NYSE:BSX) makes a variety of medical devices, but it might be best known for its pacemakers, stents and a variety of catheters.Given its diversity, the company's revenue and earnings growth pace are impressive; most diverse organizations are so diverse they aren't able to capitalize on any cyclical, product-specific tailwinds. Boston Scientific is an exception to this norm largely because a great number of its products are superior to its competitors.Numbers verify the idea. The company hasn't failed to grow the top line in any quarter since the third quarter of 2015, with the weakest of those reports being last quarter's still-solid 4.8% growth. Even that below-average quarter appears to be a one-off though. Analysts are still modeling sales growth of 8.2% this year, followed by a 9% increase next year. Earnings are apt to grow even more. * 7 Stocks to Buy From One of America's Best Pension Funds That's a big part of the reason BSX stock has been such an impressive, even if choppy, performer since 2018. Its recent weakness simply brings it back to the lower edge of a long-term and rising trading range. Village Super Market (VLGEA) Click to EnlargeVillage Super Market (NASDAQ:VLGEA) isn't for everybody. With a market cap of right around $300 million, institutional investors may find it difficult to step into a position without moving the stock's price higher, but even smaller retail investors might find trading volume is unusually light. Besides, aren't Amazon.com (NASDAQ:AMZN) and Kroger (NYSE:KR) pushing other grocers out of the business?Not quite.While it is true that the war between Kroger and Amazon is making matters tough for every other player in the grocery business, Village Super Market's small size is its advantage. Its 29 ShopRite stores aren't just grocery stores. Several of them have on-site registered dieticians, and many of its stores also operated an on-site culinary classroom, fitness studios and childcare centers. Yet, the company also offers online ordering, just like its biggest rivals do.That hasn't shielded VLGEA from some rather wild swings in recent years, but it has earned the company a spot on a list of stocks to buy sooner than later. Shares are just coming off of another higher low, and either of the most plausible ceilings are still miles above. Life Storage (LSI) Click to EnlargeIt's arguably an unhealthy mindset, but people are obsessed with keeping stuff they rarely (if ever) use, or even see.Enter Life Storage (NYSE:LSI) … a self-storage chain boasting more than 700 locations spanning 28 states. It's organized as a real estate investment trust too, so it's tax-advantaged and built to pay dividends. The current yield of 4.2% is above average for holdings with a similar risk profile, and better still, that dividend has been rising regularly since 2010 (though that growth has been plateauing lately). That may be a key part of the reason shares haven't made any net progress since the middle of last year.That could be about to change though.Analysts are calling for "earnings" of $3.13 this year (REIT earnings aren't necessarily earnings in the conventional sense) to improve to $3.21 next year. But, that outlook may not reflect the recent sale of new notes, which for the most part will be used for general corporate purposes that could include the purchase of new revenue-bearing and profit-driving properties. * 10 Tech Stocks Walloped by the Huawei Ban The chart's converging wedge pattern may actually trigger a breakout thrust once the market connects the dots. Amphastar Pharmaceuticals (AMPH) Click to EnlargeAmphastar Pharmaceuticals (NASDAQ:AMPH) may be just barely profitable, but that's about to change in a big way.Driven by explosive revenue growth from several of its products including last quarter's triple-digit revenue growth of thrombosis-prevention drug Enoxaparin, this small biopharma company is projected to improve its top line by nearly 24% next year. That should be enough grow this year's projected earnings of 32 cents per share to a whopping $1 per share of AMPH stock in 2020.That's not the only reason Amphastar is one of the top stocks to buy as we head into the latter half of 2019 though. It also has raw momentum, and it has repeatedly rewarded anyone who has bought into it on the dip like the one we've recently seen. Zillow Group (Z) Click to EnlargeThe latter half of last year was a miserable one for Zillow Group (NASDAQ:Z), and by extension, for owners of Z stock. Although real estate remained red hot through the first part of the year, a few too many red flags underscored by a couple of different disappointing quarterly reports torpedoed shares. All told, from peak to trough, Zillow Group shares lost 60% of their value.The rebound effort that has taken shape in the meantime, however, suggests traders realize they were a bit overzealous with their selling; the return of Rich Barton as CEO is helping lead them to that conclusion.And that bounce is the real deal. After logging a higher low earlier this month, Zillow Group stock has crossed back above its pivotal 200-day moving average line, and has done so on higher volume … a key missing ingredient until just recently. * 7 Utility Stocks to Trust for Retirement Cowen analyst Thomas Champion recently fanned those bullish flames too, upgrading Z stock to an "Outperform" in early April, touting the notion that Barton was the right guy to lead the company through its new house-flipping initiative. Kforce (KFRC) Click to EnlargeFinally, add Kforce (NASDAQ:KFRC) to your list of stocks to buy before or at least in June.Kforce is a staffing agency, although the term doesn't quite do the company justice. Kforce is as much of a business partner and consultant as it is a supplier of bodies, specializing in meeting higher-level, more complex corporate needs.The permanent placement business is only getting bigger. But, where Kforce has a chance to truly shine in the foreseeable future is within the contract/temporary staffing arena.Although it is nowhere on the horizon yet, more than a few corporations fear some sort of economic slowdown is in the offing. Rather than commit to a large workforce to capitalize on growth opportunities at hand, securing temporary (though indefinite) professional workers right now circumvents the risk and expense of being forced to lay off workers in the future. Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL), for instance, currently employs more contract workers than conventional employees. Even though it leaves those workers in limbo, it plays right into the hand Kforce is holding.That hasn't necessarily meant lots of stability for KFRC stock, but when taking a step back and looking at the bigger picture, it becomes clear the longer-term tide is a bullish one.Also clear is the fact that one more step forward will carry shares above a nagging resistance line that could incite a big wave of bullishness.As of this writing, James Brumley held a position in Alphabet. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 6 Marijuana Stocks With Critical Levels to Watch * 7 Utility Stocks to Trust for Retirement * 5 Large-Cap Stocks Getting Crushed in the Trade War Compare Brokers The post 7 Stocks to Buy for June appeared first on InvestorPlace.
Amphastar Pharmaceuticals, Inc. (AMPH) announced today that Jason Shandell, President and Bill Peters, CFO, will be presenting at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019 at 3:40 p.m. Pacific Time, Las Vegas, NV. This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com . Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
Amphastar (AMPH) delivered earnings and revenue surprises of 233.33% and 6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Rancho Cucamonga, California-based company said it had profit of 2 cents. Earnings, adjusted for non-recurring costs, came to 10 cents per share. The results topped Wall Street ...
RANCHO CUCAMONGA, Calif., May 09, 2019 -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March.
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
Amphastar Pharmaceuticals, Inc. (AMPH) announced that the Company will release results for its first quarter of 2019 ended March 31, 2019, after the market closes on Thursday, May 9, 2019, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (877) 881-2595, or (315) 625-3083 for international callers, five minutes before the conference. The passcode for the conference call is 8047099.
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A look at the shareholders of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often de...
HENDERSON, NV / ACCESSWIRE / April 15, 2019 / No industry is growing faster than the global cannabis market. One small-cap stock in the space beginning to gain investor favor is THC Therapeutics, Inc. ...
After all, the South San Francisco drug developer won two Food and Drug Administration approvals last year and, after slow sales of one of those drugs, it has focused on fixing manufacturing issues, nabbing European regulatory approval and getting hospitals to use the second drug, called Andexxa. At the same time, Portola (NASDAQ: PTLA) is moving forward with mid-stage studies of an experimental blood cancer drug. "Any biotech company can get bought," said Garland, who took over in October after the departure of Bill Lis, "but that's not where we spend our time." Yet with Portola's infrastructure built out, it is more attractive to larger companies that want the potential of Andexxa, the company's first-in-class antidote to blood-thinning drugs when a patient has uncontrolled bleeding.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 18) AstraZeneca plc (NYSE: AZN )(received orphan drug ...
Amphastar Pharmaceuticals, Inc., (AMPH) announced that the U.S. Food and Drug Administration (FDA) granted approval of its Abbreviated New Drug Application (“ANDA”) for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial (MDV). The company currently manufactures and distributes Enoxaparin Sodium Injection in prefilled syringe form and this approval of the Multiple Dose Vial allows the company to begin offering the full line of Enoxaparin products. Amphastar’s newly approved product was determined by the FDA to be therapeutically equivalent to Lovenox® (Enoxaparin Sodium Injection) MDV sold in the United States by Sanofi-Aventis.